Secondary Sjögren's disease where another confirmed autoimmune rheumatic or systemic inflammatory condition is the primary diagnosis.
Active fibromyalgia which is not adequately controlled in the judgment of the investigator, or participant is receiving fibromyalgia treatment that has not been stable treatment for at least 12 weeks before screening.
Any severe systemic PSjD manifestation that is not adequately controlled at baseline that may put the participant at undue risk based on the investigator's opinion.
Use of cyclophosphamide ≤ 24 weeks prior to screening.
Anti-CD20 or anti-CD19 antibody received < 6 months before screening.